How much funding has Editas Medicine raised?

Editas Medicine has raised $163.0M in total funding, most recently a Series B round.

Who are Editas Medicine's investors?

Editas Medicine's investors include Flagship Pioneering, Morgan Stanley, J.P. Morgan, Bill Gates, Polaris Partners, Third Rock Ventures.

When was Editas Medicine founded?

Editas Medicine was founded in 2013.

Where is Editas Medicine headquartered?

Editas Medicine is headquartered in Cambridge, Massachusetts, United States.

What industry is Editas Medicine in?

Editas Medicine operates in Biotech, Genomics, Healthcare, Therapeutics.

How many employees does Editas Medicine have?

Editas Medicine has 201-500 employees.

Editas Medicine

IPO

Translating CRISPR genome editing into medicines

Public · Cambridge, United States · Founded 2013 · $163.0M raised

Headquarters: Cambridge, Massachusetts
Employees: 201–500
Founded: 2013
Business Model: B2B
Website: editasmedicine.com

Total Funding: $163.0M
Last Round: $120.0M Series BAug 2015
Rounds: 2
Type: Public

About

Editas Medicine is a leading gene editing company founded in 2013, HQ Cambridge Massachusetts. Translates CRISPR genome editing into medicines for serious diseases using CRISPR/Cas9 and Cas12a nucleases. Focus on hemoglobinopathies (sickle cell, beta thalassemia), cardiovascular diseases, and oncology. Went public February 2016.

Summary

Editas Medicine is a Biotech company based in Cambridge, United States, founded in 2013. It has raised $163.0M in total across 2 rounds, most recently a $120.0M Series B round in Aug 2015. Investors include Flagship Pioneering, Morgan Stanley and J.P. Morgan.

LinkedIn X (Twitter)GitHub